We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Noninvasive Liver Fibrosis Markers in the Evaluation of Fibrosis Regression After Direct-Acting Antiviral Therapy.
- Authors
Collazos, Julio; Asensi, Víctor
- Abstract
A study published in the Journal of Infectious Diseases analyzed the course of three noninvasive markers of fibrosis (ELF, APRI, and FIB-4) in women with HIV/HCV who were treated with direct-acting antiviral (DAA) drugs. The study found that fibrosis regression occurred within the first year after treatment, but not in the following 1-2 years. The authors concluded that continued monitoring and interventions to mitigate fibrosis progression are necessary. Another study analyzed a larger cohort of patients with HCV and found similar results, with a decline in one marker (TE) over a 2-year follow-up period. The study also found that the other three markers improved within the first month of therapy and then plateaued. The authors suggest that these markers are not useful for evaluating fibrosis following treatment. The study also found no difference in the measurements of these markers between individuals with HCV monoinfection and HIV/HCV coinfection. The study suggests that TIMP-1, a component of the ELF index, may be a suitable marker for evaluating fibrosis after treatment, as its levels continued to decrease during the 1-2 year period. Overall, the study highlights the limitations of certain fibrosis markers and the need for ongoing monitoring and interventions to prevent fibrosis progression.
- Subjects
HEPATIC fibrosis; FIBROSIS; CHRONIC hepatitis C; HEPATITIS C
- Publication
Journal of Infectious Diseases, 2024, Vol 229, Issue 6, p1926
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1093/infdis/jiae095